MANNITOL INJECTION, USP 25 % — DIN 02243176
MANNITOL : 25 % · FRESENIUS KABI CANADA LTD · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is MANNITOL INJECTION, USP?
MANNITOL INJECTION, USP 25 % contains MANNITOL : 25 %. It is listed in the Health Canada Drug Product Database under DIN 02243176, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Oct-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MANNITOL INJECTION, USP used for?
Mannitol Injection, USP is indicated for the following therapeutic uses: • in the prophylaxis of oliguria in surgical procedures and traumatic conditions involving renal insult; • in the adjuvant treatment of oliguria or anuria; • the promotion of diuresis in the supportive treatment of edema and ascites; • the reduction of elevated cerebrospinal fluid pressure; • in the adjunctive treatment in certain drug intoxications.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Mannitol cost around the world?
Mannitol is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 8 | 13 | SAR███.██ |
| Lebanon | public price (USD, Decision 119/1) | 4 | 12 | USD███.██ |
| Romania | max producer price | 4 | 12 | RON███.██ |
| South Africa | single exit price | 7 | 11 | ZAR███.██ |
| Greece | producer price (ex-factory) | 10 | 10 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 4 | 7 | NOK███.██ |
| Morocco | PPV (public price) | 3 | 4 | MAD███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
78 pack listings across 47 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Mannitol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Mannitol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Mannitol, across 9 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 2 | 2 | OSMITROL INJECTION 10%, OSMITROL INJECTION 20% | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | MANNITOL INJECTION, USP | Sourceable in Canada |
| ICU MEDICAL CANADA INC | 1 | 1 | MANNITOL INJECTION USP | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | MANNITOL INJECTION USP | Sourceable in Canada |
| ABBOTT LABORATORIES, LIMITED | 2 | 0 | MANNITOL INJ 10% ABBOVAC, MANNITOL INJ 5% ABBOVAC | No marketed DIN |
| ASTRA PHARMA INC. | 1 | 0 | MANNITOL INJ 25% | No marketed DIN |
| INTERNATIONAL MEDICATION SYSTEMS LTD. | 1 | 0 | MANNITOL INJ 25% | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 25 % |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 50 mL single use flip-top vial in packages of 25. |
| Storage | Store at 15 °C to 30 °C. Protect from freezing. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Mannitol |
|---|---|
| ATC code | B05BC01 |
| AHFS class | 40:28.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02243176 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243176 |
| Brand name | MANNITOL INJECTION, USP |
| Generic / active ingredient | MANNITOL : 25 % |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Ethical |
| ATC code | B05BC01 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05BC |
| Current status | MARKETED |
| Status date | 19-Oct-2022 |
| Original market date | 2002-04-09 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Mannitol in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PFIZER CANADA ULC, last seen 10 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MANNITOL INJECTION USP | 20 % | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | 00038016 |
| MANNITOL INJECTION USP | 25 % | SOLUTION | PFIZER CANADA ULC | MARKETED | 00038024 |
| OSMITROL INJECTION 10% | 10 % | SOLUTION | BAXTER CORPORATION | MARKETED | 00060410 |
| OSMITROL INJECTION 20% | 20 % | SOLUTION | BAXTER CORPORATION | MARKETED | 00060437 |
| MANNITOL INJ 10% ABBOVAC | 100 MG | LIQUID | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | 00037990 |
| MANNITOL INJ 25% | 250 MG | LIQUID | ASTRA PHARMA INC. | CANCELLED POST MARKET | 00729183 |
| MANNITOL INJ 25% | 250 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00243809 |
| MANNITOL INJ 5% ABBOVAC | 50 MG | LIQUID | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | 00037982 |
2 · Same class — other molecules in ATC B05BC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Mannitol | MANNITOL INJ 10% ABBOVAC · MANNITOL INJ 25% · MANNITOL INJ 5% ABBOVAC · MANNITOL INJECTION USP · +3 more | 9 | 5 | Yes |
| Carbamide | CARBAMEX 330MGMS | 1 | 0 | Not in Canada |
| Carbamide, Combinations | DIUERB TAB | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05BA | Amino Acids · Carbohydrates · Combinations · Fat Emulsions | 150 | 38 |
| B05BB | Electrolytes · Electrolytes With Carbohydrates | 90 | 27 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MANNITOL INJECTION, USP called?
The same molecule, Mannitol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Mannitol | Latin | Lebanon, Norway, Saudi Arabia |
| Bronchitol | Latin | Australia, Czechia, Norway |
| Mannitol Baxter Viaflo | Latin | Norway |
| Aridol | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.